

Dysarthria

[View the current Dysarthria InDepth page on BioPortfolio.com](#) (PDF)

(<http://www.bioportfolio.com/indepth/Dysarthria.html>) - Regularly Updated.

Dysarthria is a motor speech disorder resulting from neurological injury, characterised by poor articulation . Any of the speech subsystems can be affected. Disarthric speech is due to some disorder in the nervous system, which in turn hinders control over, for example, tongue, throat, lips or lungs. Swallowing problems, dysphagia, are often present. Cranial nerves that control these muscles include the facial nerve , the glossopharyngeal nerve , the vagus nerve , and the hypoglossal nerve . ([From the Wikipedia article Dysarthria](#) .)

Recent Publications on Dysarthria:



- [The Redesign and Re-evaluation of an Internet-Based Telerehabilitation System for the Assessment of Dysarthria in Adults.](#)
*A previous study revealed that reliable assessment of dysarthria was...*19th November, 2009
Division of Speech Pathology.- Telemed J E Health. 2009 Nov;15(9):840-850. ([DOI Direct Link](#))
- [A novel presenilin1 mutation \(Q223R\) associated with early onset Alzheimer's disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF.](#)
*Background and purpose: A novel presenilin1 (PSEN1) mutation associated...*17th November, 2009
Department of Neurology, University Hospital, Ulm, Germany.- Eur J Neurol. 2009 Nov 12. ([DOI Direct Link](#))
- [Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.](#)
*BACKGROUND: Central nervous system (CNS) complications of Langerhans cell...*13th November, 2009
Texas Children's Cancer Center/Hematology Service, Houston, Texas.- Pediatr Blood Cancer. 2009 Nov 11. ([DOI Direct Link](#))
- [A pernicious leucoencephalopathy.](#)
*Pernicious anaemia may manifest various neurological symptoms and signs...*12th November, 2009
Department of Neurology, St Vincent's University Hospital, Elm Park,- Ir Med J. 2009 Oct;102(9):292-4.
- [Childhood chorea with cerebral hypotrophy: a treatable GLUT1 energy failure syndrome.](#)
*OBJECTIVE: To expand the spectrum of glucose transporter type 1 deficiency...*11th November, 2009
Department of Neurology, Hospital Universitari Sant Joan de Deu,- Arch Neurol. 2009 Nov;66(11):1410-4. ([DOI Direct Link](#))
- [Miglustat therapy in juvenile Sandhoff disease.](#)
*GM(2)-gangliosidosis is a rare and heterogeneous inherited metabolic...*10th November, 2009
Department of Neurology, Ullevål University Hospital, Oslo and Faculty of- J Inherit Metab Dis. 2009 Nov 4. ([DOI Direct Link](#))
- [Pallidal deep brain stimulation in primary cervical dystonia with phasic type : clinical outcome and](#)

[postoperative course.](#)

*OBJECTIVE: The purpose of this study was to analyze in detail the...*7th November, 2009
Department of Neurosurgery, Bongseng Memorial Hospital, Busan, Korea.- J Korean Neurosurg Soc. 2009 Oct;46(4):346-50. Epub 2009 Oct 31. ([DOI Direct Link](#))

- [A phonation therapy approach for Mandarin-English bilingual clients with dysarthria.](#)
*This study aims to measure the speech intelligibility of Mandarin-English...*4th November, 2009
Group Special Education, Auckland, New Zealand.- Clin Linguist Phon. 2009 Oct;23(10):762-79.
- [\[A case of non-traumatic tension pneumocephalus 12 years after initial ventriculo-peritoneal shunt\]](#)
*The authors presented a patient with non-traumatic tension pneumocephalus...*4th November, 2009
Department of Neurosurgery, Chugoku Rousai Hospital, Japan.- No Shinkei Geka. 2009 Oct;37(10):995-9.
- [The existence of phonatory instability in multiple sclerosis: an acoustic and electroglottographic study.](#)
*Dysarthria and phonatory symptomatology are often reported by patients...*31st October, 2009
Department of Neurology, Athens Naval Hospital, Athens, Greece.- Neurol Sci. 2009 Oct 30. ([DOI Direct Link](#))
- [Statistical Models of F2 Slope in Relation to Severity of Dysarthria.](#)
*Objective: This study investigated the distribution of second-formant (F2)...*30th October, 2009
Department of Communication Sciences and Disorders, Louisiana State- Folia Phoniatr Logop. 2009 Oct 28;61(6):329-335. ([DOI Direct Link](#))
- [Laryngeal function: a comparative analysis between children and adults subsequent to traumatic brain injury.](#)
*OBJECTIVE: To evaluate laryngeal function and speech disorders in children...*28th October, 2009
Division of Speech Pathology and Audiology, The University of Queensland,- J Head Trauma Rehabil. 2009 Sep-Oct;24(5):374-83. ([DOI Direct Link](#))
- [Inflammatory pseudotumor of the parapharyngeal space: A case report.](#)
*Inflammatory pseudotumor is an idiopathic granuloma characterized by...*28th October, 2009
Department of Head and Neck Surgery and Oncology, International University- Auris Nasus Larynx. 2009 Oct 24. ([DOI Direct Link](#))
- [Chronic Deep Brain Stimulation for Segmental Dystonia.](#)
*Fourteen consecutive patients with segmental dystonia underwent chronic...*22nd October, 2009
Department of Neurology, Universitätsklinikum Mannheim, Mannheim, Germany.- Stereotact Funct Neurosurg. 2009 Oct 21;87(6):379-384. ([DOI Direct Link](#))
- [Short-term prognosis for speech and language in first stroke patients.](#)
*OBJECTIVE: To evaluate the factors that can influence evolution of...*20th October, 2009
Department of Neurology, State University of Campinas, Campinas, SP,- Arq Neuropsiquiatr. 2009 Sep;67(3B):849-55.

Dysarthria Patents:



- 7368531- [Human secreted proteins](#)
- 7446176- [12 human secreted proteins](#)
- 7446181- [Antibodies that bind human Dickkopf-1 proteins](#)
- 7449575- [Substituted diamino-1,3,5-triazine derivatives](#)
- 7459156- [Antibodies that mimic actions of neurotrophins](#)

- 7459531- [50 Human secreted proteins](#)
- 7462495- [Methods and compositions for use in diagnosing and characterizing chronic immune disease](#)
- 7465795- [Compounds and uses thereof](#)
- 7482013- [Albumin fusion proteins](#)
- 7488486- [Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical episode of an incurable disease and methods of use thereof](#)
- 7493172- [Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition](#)
- 7442705- [HIV replication inhibiting pyrimidines and triazines](#)
- 7438667- [Oral-lever resistance exercise device](#)
- 7429238- [Systems and methods for the generation of crystalline polymorphs](#)
- 7369899- [Minimally invasive systems for locating an optimal location for deep brain stimulation](#)
- 7373294- [Intonation transformation for speech therapy and the like](#)
- 7381800- [Antibodies to HBIMF63 polypeptide](#)
- 7384748- [Compositions and methods for detecting and treating motor neuron disorders](#)
- 7390637- [Keratinocyte derived interferon](#)
- 7393934- [Human G-protein chemokine receptor \(CCR5\) HDGMR10](#)
- 7407743- [Kit and method of screening wilson's disease](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7425556- [Compounds and uses thereof](#)
- 7427601- [Method for treating tremor](#)
- 7501123- [Human G-protein chemokine receptor \(CCR5\) HDGMR10](#)
- 7507413- [Albumin fusion proteins](#)
- 7579168- [Human Dickkopf-related nucleic acid molecules](#)
- 7579313- [Transglutaminase inhibitors and methods of use thereof](#)
- 7585629- [Compositions and methods for spinocerebellar ataxia](#)
- 7585861- [HIV inhibiting 1,2,4-triazines](#)
- 7585870- [HIV replication inhibiting pyrimidines and triazines](#)
- 7591779- [Adaptation resistant anti-stuttering devices and related methods](#)
- 7592010- [Albumin fusion proteins](#)
- 7608406- [Diagnostic markers of stroke and cerebral injury and methods of use thereof](#)
- 7608726- [Substituted indolepyridinium as anti-infective compounds](#)
- 7611910- [Method for diagnosis of alzheimer's disease](#)
- 7569384- [Albumin fusion proteins](#)
- 7563808- [Methods for treating cognitive impairments or dementia](#)
- 7560433- [Treatment of multiple sclerosis \(MS\)](#)
- 7507414- [Albumin fusion proteins](#)
- 7514079- [Antibodies that specifically bind to neurokinin B](#)
- 7514427- [1,5,6,-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-infective agents](#)
- 7517529- [Treatment of type I diabetes](#)
- 7521424- [Albumin fusion proteins](#)
- 7527938- [Methods for diagnosis and treatment of chronic immune diseases](#)
- 7531548- [HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines](#)
- 7541044- [Administration of 5T4 antigen and immune response of cells expressing 5T4 and CEA antigens](#)
- 7544669- [Polynucleotide therapy](#)
- 7558622- [Mesh network stroke monitoring appliance](#)
- 7615639- [1-pyridyl-benzofuro\[3,2-b\]pyridin-2\(1H\)-ones](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

